WASHINGTON — The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases. A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen’s version of AbbVie’s
